Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electroacupuncture plus envafolimab, gemcitabine, and cisplatin for unresectable biliary tract cancer
ChiCTR2400083982Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- May 2024
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, gemcitabine and cisplatin in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
envafolimabgemcitabinecisplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2400083982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083982.